Drug-induced lupus erythematosus secondary to nafcillin: the first reported case

Rheumatol Int. 2004 Jul;24(4):242-3. doi: 10.1007/s00296-003-0356-6. Epub 2003 Dec 5.

Abstract

With an estimated incidence of 15-30,000 cases per year in the United States, drug-induced lupus erythematosus (DIL) is an uncommon iatrogenic condition. The number of implicated medications increases each year. We report the first case of DIL secondary to nafcillin administration in a patient with a prosthetic aortic valve and methicillin-sensitive Staphylococcus aureus who developed a facial rash and lower back pain.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / adverse effects*
  • Humans
  • Lupus Erythematosus, Systemic / chemically induced*
  • Lupus Erythematosus, Systemic / pathology
  • Male
  • Middle Aged
  • Nafcillin / adverse effects*
  • Staphylococcal Skin Infections / complications
  • Staphylococcal Skin Infections / drug therapy
  • Staphylococcal Skin Infections / pathology
  • Staphylococcus aureus / isolation & purification
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Nafcillin